November 3, 2015 / 6:32 AM / 2 years ago

BRIEF-Esperite will end year behind projected revenue

Nov 3 (Reuters) - Esperite NV

* Says consolidated revenue increased in Q3 over same period of last year by 5 percent

* Genoma continues its growth over reporting period with a 45 percent increase compared to Q2

* Says Genoma expectations for Q4 and 2016 are high

* Cryosave maintains new client intake with revenue for Q3 being in line with revenue realised in Q2

* Says growth for Cryosave revenue is expected for Q4

* Says as result of 2 to 3-month lag announced in 2015 half year report and carried out until Q1 2016, it will end year behind projected revenue

* Says high-growth potential of new markets is expected to have a positive effect on results already in Q4

* We are confident in our vision and strategy, results are backing us up - CEO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below